Studies were carried out on the effect of dianhydrogalactitol on a human neuroblastoma cell line in culture. The drug was cytotoxic at concentrations of 5 micrograms/ml and 10 micrograms/ml for 1 hour, but not at 1 microgram/ml. Flow cytometry of DNA showed that cell kill was preceded by a transient accumulation of cells in early S at 10 hours, and in late S at 36 hours. Smaller increases in the percent of cells in S phase were seen after treatment with 1 microgram/ml, without cell kill. It may be concluded that dianhydrogalactitol causes an S-phase block, followed by death of cells in late S at concentrations above 5 micrograms/ml.

Download full-text PDF

Source
http://dx.doi.org/10.3109/07357908509039794DOI Listing

Publication Analysis

Top Keywords

human neuroblastoma
8
neuroblastoma cell
8
concentrations micrograms/ml
8
cell kill
8
cytokinetics human
4
cell
4
cell treatment
4
treatment dianhydrogalactitol
4
dianhydrogalactitol studies
4
studies carried
4

Similar Publications

Exploring apoptotic pathways in SH-SY5Y neuroblastoma cells: combined effects of napabucasin and doxorubicin.

Folia Morphol (Warsz)

January 2025

Department of Gynecology and Obstetrics, Faculty of Medicine, Atatürk University, Erzurum, Turkey.

Background: Neuroblastoma often begins in infancy and one of the most common types of cancer among children is someone. Napabucasin (NP) (BBI608), a natural naphthoquinone emerging as a novel inhibitor of STAT3, has been found to effectively kill cancer stem-like tumor cells. On the other hand, the effect of Napabucasin on SH-SY5Y cells is currently unclear.

View Article and Find Full Text PDF

Famotidine is an H2 receptor antagonist and is currently used on a large scale in gastroenterology. However, Famotidine may also cause severe toxicity to organ systems, including the blood system, digestive system, and urinary system. The objective of this study was to scientifically and systematically investigate the adverse events (AEs) of Famotidine in the real world through the FDA Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Induced pluripotent stem cell (iPSC) technology is revolutionizing cell biology. However, the variability between individual iPSC lines and the lack of efficient technology to comprehensively characterize iPSC-derived cell types hinder its adoption in routine preclinical screening settings. To facilitate the validation of iPSC-derived cell culture composition, we have implemented an imaging assay based on cell painting and convolutional neural networks to recognize cell types in dense and mixed cultures with high fidelity.

View Article and Find Full Text PDF

Machine Learning Approaches for Neuroblastoma Risk Prediction and Stratification.

Crit Rev Oncog

January 2025

Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.

Machine learning (ML) holds great promise in advancing risk prediction and stratification for neuroblastoma, a highly heterogeneous pediatric cancer. By utilizing large-scale biological and clinical data, ML models can detect complex patterns that traditional approaches often overlook, enabling more personalized treatments and better patient outcomes. Various ML techniques, such as support vector machines, random forests, and deep learning, have shown superior performance in predicting survival, relapse, and treatment responses in neuroblastoma patients compared to conventional methods.

View Article and Find Full Text PDF

Senescence, a crucial yet paradoxical phenomenon in cellular biology, acts as a barrier against cancer progression while simultaneously promoting aging and age-related pathologies. This duality underlines the importance of precise monitoring of senescence response, especially with regard to the proposed use of drugs selectively removing senescent cells. In particular, little is known about the role of senescence in neurons and in neurodegenerative diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!